These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3610904)

  • 41. Comparative activities of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. in pure and mixed cultures.
    Soriano F; Ponte MC
    Antimicrob Agents Chemother; 1984 Jul; 26(1):39-41. PubMed ID: 6089653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative in vitro activity of 5 cephalosporins with other antibiotics tested against 887 recent clinical isolates.
    Wasilauskas BL
    Chemotherapy; 1981; 27(6):416-22. PubMed ID: 7297171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3959-62. PubMed ID: 16982780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
    Verbist L; Glupczynski Y
    Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stimulatory effect of cefodizime on macrophage-mediated phagocytosis.
    Oishi K; Matsumoto K; Yamamoto M; Morito T; Yoshida T
    J Antibiot (Tokyo); 1989 Jun; 42(6):989-92. PubMed ID: 2737956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The combination of aztreonam and cefozopran against Stenotrophomonas maltophilia.
    Kataoka D; Tanaka Y
    J Infect Chemother; 2004 Feb; 10(1):62-4. PubMed ID: 14991523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol; 1987 Dec; 6(6):688-90. PubMed ID: 3126062
    [No Abstract]   [Full Text] [Related]  

  • 50. The in vitro responses of Bacteroides fragilis to Moxalactam, Cefotaxime, Cefmetazole, Josamycin and erythromycin.
    Soriano F; Ponte MC; Gaspar MC
    J Clin Pathol; 1982 Oct; 35(10):1166-7. PubMed ID: 6290543
    [No Abstract]   [Full Text] [Related]  

  • 51. Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens).
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):43-8. PubMed ID: 7587049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
    Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
    J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of cefepime and cefotaxime compared to six other agents against 350 penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Gomez-Lus R; Navarro C; Egido P; Aspiroz C; Goñi P; Vergara Y; Garcia C; Duran E; Castillo J; Rubio MC
    J Chemother; 2000 Feb; 12(1):17-21. PubMed ID: 10768511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergy study of carumonam and ceftazidime with aminoglycosides.
    Ahmet Z; Houang E
    J Antimicrob Chemother; 1987 Aug; 20(2):288-90. PubMed ID: 3312142
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative in vitro activity of RU 28965 against Chlamydia trachomatis.
    Cevenini R; Sambri V; La Placa M
    Eur J Clin Microbiol; 1986 Oct; 5(5):598-600. PubMed ID: 3536506
    [No Abstract]   [Full Text] [Related]  

  • 58. Sub-MIC concentrations of cefodizime interfere with various factors affecting bacterial virulence.
    Braga PC; Sasso MD; Sala MT
    J Antimicrob Chemother; 2000 Jan; 45(1):15-25. PubMed ID: 10629008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of aztreonam on throat and stool flora of cancer patients.
    Jones PG; Bodey GP; Swabb EA; Rosenbaum B
    Antimicrob Agents Chemother; 1984 Dec; 26(6):941-3. PubMed ID: 6543108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-627, a novel carbapenem: in-vitro activity against anaerobes.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García I; Fresnadillo-Martínez J
    J Antimicrob Chemother; 1994 Jan; 33(1):183-6. PubMed ID: 8157563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.